The clinical efficacy of single morning doses of levodopa methyl ester: Dispersible Madopar and Sinemet plus in Parkinson disease

M. J. Steiger, F. Stocchi, L. Bramante, S. Ruggieri, N. P. Quinn

Research output: Contribution to journalArticle

Abstract

For many patients with Parkinson disease and levodopa-related motor fluctuations, the latency to onset of action of a single dose of a levodopa preparation may be both long and variable. In an effort to find a more rapidly acting and reliable preparation of levodopa, we therefore studied the efficacy of single doses of an oral solution of 250 mg of levodopa methyl ester (ME) with benserazide, 50 mg and of a molar equivalent dose of dispersible Madopar (DM) (50/200) in 13 patients in the fasting state after overnight drug withdrawal. The response of seven of these patients was compared to that after two Sinemet 25/100. The latency to 'on' was equally fast with ME and DM, and significantly faster than after standard Sinemet. The duration of 'on' was similar with all three. Because of this more rapid relief of 'off' periods, both ME and DM offer a potential clinical advantage over standard preparations of levodopa.

Original languageEnglish
Pages (from-to)501-504
Number of pages4
JournalClinical Neuropharmacology
Volume15
Issue number6
Publication statusPublished - 1992

Keywords

  • Dispersible Madopar
  • Levodopa methyl ester
  • Parkinson disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'The clinical efficacy of single morning doses of levodopa methyl ester: Dispersible Madopar and Sinemet plus in Parkinson disease'. Together they form a unique fingerprint.

  • Cite this